Skip to content
FDA Approves Tralokinumab for Atopic Dermatitis episode artwork

Jan 10, 2022 7 min

FDA Approves Tralokinumab for Atopic Dermatitis

from HCPLive Podcasts Hosted by HCPLive.com

DocTalk returns in 2022 with a discussion of the recent Food and Drug Administration (FDA) approval of tralokinumab for the treatment of moderate-to-severe atopic dermatitis in adult patients. For this episode, Jonathan Silverberg, MD, PhD, MPH, discusses the ECZTRA trials, 3 phase 3 trials that evaluated the efficacy of the biologic as a monotherapy as well as a combination therapy with topical corticosteroids. Tralokinumab is the first and only biologic approved by the FDA that binds to and inhibits the interleukin (IL)-13 cytokine, noted as a key driver of signs and symptoms of atopic dermatitis. Dr. Silverberg speaks on what this new treatment means for the future of atopic dermatitis management.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

FDA Approves Tralokinumab for Atopic Dermatitis

0:00 7:54

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of HCPLive Podcasts?

This episode is 7 minutes long.

When was this HCPLive Podcasts episode published?

This episode was published on January 10, 2022.

Can I download this HCPLive Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.